Serum Overexpression of MicroRNA-10b in Patients with Bone Metastatic Primary Breast Cancer

Zhao, Fang; Gd, Hu; Xf, Wang; Xh, Zhang; Yk, Zhang; Zs, Yu

doi:10.1177/147323001204000304

Cited by 73 publications

(64 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sun et al showed that serum miRNA-155 can be used as a diagnostic marker for breast cancer (16). It has also been demonstrated that serum miRNA-10b expression is significantly higher in breast cancer patients with bone metastases, and that it can therefore be used as a tumor marker for breast cancer bone metastasis (17). However, previous studies on serum miRNAs have not provided a standardized internal standard.…”

Section: A B C Dmentioning

confidence: 99%

Serum expression levels of microRNA-382-3p, −598-3p, −1246 and −184 in breast cancer patients

Zhu

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. The purpose of the present study was to investigate the serum levels of microRNA (miRNA/miR)-382-3p, -598-3p, -1246 and -184 in breast cancer patients and to assess their feasibility as biomarkers for breast cancer screening. Serum samples were obtained from 100 breast cancer patients and 40 age-matched healthy control subjects in Taizhou Central Hospital (Taizhou, Zhejiang, China) between January 2013 and September 2014. The serum expression levels of miR-382-3p, -598-3p, -1246 and -184 were determined by stem-loop reverse transcription-quantitative polymerase chain reaction. Receiver operating characteristic curves were drawn to evaluate the sensitivity and specificity of the serum miRNA expression levels for the screening of breast cancer. miR-382-3p and -1246 were significantly upregulated in the serum of the breast cancer patients, while miR-598-3p and -184 were significantly downregulated. The sensitivity and specificity to detect breast cancer were as follows: miR-382-3p, 52.0 and 92.5%; miR-598-3p, 95.0 and 85.0%; miR-1246, 93.0 and 75.0%; and miR-184, 87.5 and 71.0%, respectively. The expression levels of the four serum miRNAs were not correlated with the patients' clinical stage. In summary, miR-382-3p, -598-3p, -1246 and -184 are all involved in the development of breast cancer, and are promising biomarkers for breast cancer detection. IntroductionBreast cancer has become the most common cancer in women in China, accounting for 12.2% of all newly diagnosed breast cancers and 9.6% of all mortalities from breast cancer worldwide (1). Early detection of breast cancer is the key to successful treatment and patient survival. Mammographies, magnetic resonance imaging and ultrasound are being used for the screening of breast cancer, but these techniques have limitations such as low sensitivity and specificity (2). Finding effective biomarkers is vital for the screening of breast cancer.MicroRNAs (miRNAs/miRs) are a group of small non-coding RNAs (3), which can bind to the 3' untranslated region (UTR), the 5' UTR (4) or the coding region (5) of target mRNA. miRNAs play important roles in the negative regulation of gene expression in a post-transcriptional manner, and are involved in a number of signal transduction pathways, including cell proliferation, differentiation, apoptosis, immune response and angiogenesis (6). Previous studies have revealed the abnormal expression of miRNAs in the development and progression of breast cancer (7), and miRNAs are closely linked with tumor-associated signal transduction pathways (8). In our previous study, 10 miRNAs that were significantly differentially expressed were found by the second generation of high-throughput sequencing technology, Illumina Hiseq2500 (9). In the present study, 4 miRNAs, miR-382-3p, -598-3p, -1246 and -184, were further investigated. The purpose of this study was to investigate the serum levels of these miRNAs in breast cancer patients and to assess their feasibility as biomarkers for breast cancer screening. Materials and methods Subje...

show abstract

Section: A B C Dmentioning

confidence: 99%

Serum expression levels of microRNA-382-3p, −598-3p, −1246 and −184 in breast cancer patients

Zhu

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…MicroRNA-10b was identified as an miRNA highly expressed in metastatic breast cancer cell lines, able to generate metastases when growing as primary mammary tumor in mice (Ma et al, 2007). Several recent studies show that increased miR-10b levels have been associated with bone (Zhao et al, 2012) and brain metastases (Chiang and Massagué, 2008) as well as spread to the lymph nodes (Chen et al, 2013) in patients with breast cancer. Whether miR-10b is a prognostic marker in patients with breast cancer has been studied extensively, but the conclusions are inconsistent.…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of microRNA-10b overexpression in breast cancer: a meta-analysis

et al. 2016

View full text Add to dashboard Cite

ABSTRACT. Many microRNAs (miRNAs) exhibit altered expression levels in cancers, and they may be considered as valuable prognostic biomarkers for cancers. Here we aimed to summarize the recent advances in miR10b involvement in human breast cancer and analyze the predicting role of miR-10b for survival. We searched, Embase, and Wanfang databases to identify studies on the prognostic role of miR-10b expression in breast cancer. A total of 770 patients from 7 eligible studies were included in the analysis. Pooled risk ratios (RRs) with 95% confidence interval (95%CI) were calculated to estimate the effect. Our results showed that high miR10b expression in patients with breast cancer was significantly associated with poor disease-free survival (DFS) (RR = 1.53; 95%CI = 1.06-2.21; P = 0.02). However, no significant association between miR-10b and overall survival was found in overall studies. Subgroup analysis indicated that high expression of miR-10b was significantly correlated with DFS in Asia (RR = 2.94; 95%CI = 1.71-5.05). The present meta-analysis demonstrated that high expression of miR-10b might predict poor survival in patients with

show abstract

“…43 Moreover, miR-10b could be a circulating marker of bone metastasis in regard of the high level of miR-10b in serum of breast cancer patients with the disease. 44 Finally, it is of interest to note that these early bone-homing steps may be reversed by acute expression of the tumour suppressor miRNA-31. Indeed, in a mouse model of bone metastasis, the induction of miRNA-31 triggered regression of already-seeded bone metastasis.…”

Section: Mirnas Regulate Bone Marrow Invasion and Colonisation By Canmentioning

confidence: 99%

Tumour-derived miRNAs and bone metastasis

Croset

Kan

Clézardin³

2015

BoneKEy Reports

View full text Add to dashboard Cite

Skeletal metastases are complications of epithelial cancers, among which breast, prostate and lung carcinomas are the most osteotropic. In primary tumours, a subset of cancer cells undergoes epithelial-mesenchymal transition, acquires mobility to migrate into the surrounding stroma and seeds at distant sites to grow. The specific development of bone metastasis requires the recruitment of circulating tumour cells in the bone marrow, their adaptation to survive in the surrounding microenvironment where they alter the functions of osteoclasts and osteoblasts, and hijack signals coming from the bone matrix. Each of the molecular pathways underlining these steps is regulated by multiple factors, through the tight control of genes expressed by cancer cells interacting with cells from the bone microenvironment. In this context, miRNAs can act as master regulators of gene expression to control multiple aspects of bone metastasis formation, including cancer cell escape from the primary tumour site, cancer cell dissemination to bone and invasion of the bone marrow, as well as secondary outgrowth and tumour-stroma cell interactions. In the clinic, specific miRNA signatures have been identified in osteotropic cancer cells, raising the possibility that miRNAs could be used as biomarkers of bone metastasis. The regulatory activity of miRNAs in the bone microenvironment also suggests that miRNAs could be promising therapeutic targets.

show abstract

Serum Overexpression of MicroRNA-10b in Patients with Bone Metastatic Primary Breast Cancer

Abstract: These results suggest that serum miR-10b may be a useful biomarker for the identification of bone metastatic breast cancer.

Cited by 73 publications

References 37 publications

Serum expression levels of microRNA-382-3p, −598-3p, −1246 and −184 in breast cancer patients

Serum expression levels of microRNA-382-3p, −598-3p, −1246 and −184 in breast cancer patients

Prognostic significance of microRNA-10b overexpression in breast cancer: a meta-analysis

Tumour-derived miRNAs and bone metastasis

Contact Info

Product

Resources

About